DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0269380 A1 Baker, JR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20090269380A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269380 A1 Baker, JR. et al. (43) Pub. Date: Oct. 29, 2009 (54) METHODS OF TREATING FUNGAL YEAST (22) Filed: Apr. 27, 2009 AND MOLD INFECTIONS Related U.S. Application Data (75) Inventors: James R. Baker, JR. Ann Arbor, (60) Provisional application No. 61/048,075, filed on Apr. MI (US); Mary R. Flack, Ann 25, 2008, provisional application No. 61/129,962, Arbor, MI (US); Susan M. Ciotti, filed on Aug. 1, 2008, provisional application No. Ann Arbor, MI (US); Joyce A. 61/115,879, filed on Nov. 18, 2008. Sutcliffe, West Newton, MA (US) Publication Classification Correspondence Address: (51) Int. Cl. FOLEY AND LARDNER LLP AOIN 25/00 (2006.01) SUTESOO (52) U.S. Cl. ........................................................ 424/405 3OOOK STREET NW (57) ABSTRACT WASHINGTON, DC 20007 (US) The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in (73) Assignee: Nanobio Corporation human Subjects comprising topically administering to a human Subject in need thereof an antifungal nanoemulsion (21) Appl. No.: 12/430,700 composition. Patent Application Publication Oct. 29, 2009 Sheet 1 of 26 US 2009/0269380 A1 u?XISO?u,Ku?A||3C] uo|s|nuuÐOueN.IeInô Patent Application Publication Oct. 29, 2009 Sheet 3 of 26 US 2009/0269380 A1 ;· Fire ?uffir E .1:1±”?öjiäö?öjö-elozeuopeu?i - *x*j*******************(~~~r ufi or--------------------------------------~--~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&No. ufrical Patent Application Publication Oct. 29, 2009 Sheet 4 of 26 US 2009/0269380 A1 uO??0\/JOUusque?.00W *********ggæskæog. Patent Application Publication Oct. 29, 2009 Sheet 6 of 26 US 2009/0269380 A1 ??Mou9||eNueau?Tp??0???eunu??u???seguuou?06ue?O:9?un61– (queussessyo?u?ºu?ueId) toi aftiet) i.ec.) ex paioaiei Patent Application Publication Oct. 29, 2009 Sheet 7 of 26 US 2009/0269380 A1 eeuwp??0æJJVu??seauoade???os?sÁIeuvuu?u??u|| (queuussassyo?u?auu?ueId) 3 i3Seguidi afuiet.) Lean) :/?un61– ELLule: EY p3xy Patent Application Publication Oct. 29, 2009 Sheet 8 of 26 US 2009/0269380 A1 euo?sa?ex,aunoleo?6olooÁIN?ouosqueduuoºo:8ºun61-I oe?uºdpue(„Z00-£IN„)uo?sinuaoueN -8. --------------------------- ------- -3- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- eley end leobooo/W Patent Application Publication Oct. 29, 2009 Sheet 9 of 26 US 2009/0269380 A1 Patent Application Publication Oct. 29, 2009 Sheet 10 of 26 US 2009/0269380 A1 penu??uOO’6?un61– Patent Application Publication Oct. 29, 2009 Sheet 12 of 26 US 2009/0269380 A1 ?.0||C?? S?JOds Patent Application Publication Oct. 29, 2009 Sheet 13 of 26 US 2009/0269380 A1 ZLeInfi!-- Patent Application Publication Oct. 29, 2009 Sheet 14 of 26 US 2009/0269380 A1 ueuunHO?u,KuÐA||3C]uo|s|nuu?OueN:£|?un61– SunOH?7Z?eu?XISJÐAepeO Patent Application Publication Oct. 29, 2009 Sheet 15 of 26 US 2009/0269380 A1 KuÐA??aqleuuedAu3A||3C]Ieuuep?dE - MM 0099 009 000€E ©009Z(º 000z& !,9 009900‰?i Patent Application Publication Oct. 29, 2009 Sheet 16 of 26 US 2009/0269380 A1 C#X00-8NEX00-£IN -?–oose- ?0?Ê {005?) ?002 {0.05T {000T 00$ Patent Application Publication Oct. 29, 2009 Sheet 17 of 26 US 2009/0269380 A1 oHg+uue-,3/3n? Patent Application Publication Oct. 29, 2009 Sheet 18 of 26 US 2009/0269380 A1 sunouvzqesquuep?deupisau?ºwsu?ejozeuoo?Wgosla^eºT‘ZI,?un61-I *(c11a)uo?eo?iddeIeo!do)d???e Patent Application Publication Oct. 29, 2009 Sheet 19 of 26 US 2009/0269380 A1 sunouyzjesquuuapupisau?ºwsu?3Iozeuoo?IN?osla^3T'8||3.Infi? '(GIIG)uo?eo||ddeIeo!do?da??e ensses foE Sri Patent Application Publication Oct. 29, 2009 Sheet 20 of 26 US 2009/0269380 A1 zuuoZZºg:eeuw6u?soqu??nO zuuo£'º:eeuweIpp?W „uoG’O:eeuwuauu! Patent Application Publication Oct. 29, 2009 Sheet 21 of 26 US 2009/0269380 A1 ERHOO?HEINNI** ERHOOETCICIIIN…………..><!-----….(……. :u?uO??eu?u00uOO No.= Ápn?Suo?sn???CIIeua?e"?:OZ?un61-I u?XISJÐAepeOueUunHu? ?Iduues J3AepeoueuunH Patent Application Publication Oct. 29, 2009 Sheet 22 of 26 US 2009/0269380 A1 SunOH?7Z?eu?XISS?uuJep?dEJ?AepeO ueuunHO?u,uO?Sn???C]|ed??eT:LZ?un61– Patent Application Publication Oct. 29, 2009 Sheet 24 of 26 US 2009/0269380 A1 Oau?=Go'sinouºpueoau?:6u?sopGIG (GIE:%szo)slujeqt)|- |–)| |-(GO:%s(o)s(ulea—|--|— OGZ OOZ OG|| 09 enSSI) ueuf 100 fin Patent Application Publication ueuf 100 firl Patent Application Publication Oct. 29, 2009 Sheet 26 of 26 US 2009/0269380 A1 X00-EN%9'0gouo?e0||ddwyeuO U2, (O 108 for US 2009/0269380 A1 Oct. 29, 2009 METHODS OF TREATING FUNGAL YEAST another term for dermatophyte infections of the nail. Second AND MOLD INFECTIONS ary bacterial infections may develop from the fungal infec tion. CROSS-REFERENCE TO RELATED 0005 Tinea is very common, especially among children, APPLICATIONS and may be spread by skin-to-skin contact, as well as via contact with contaminated items such as hairbrushes or 0001. This application claims priority of U.S. Provisional through the use of the same toilet seat as an infected indi Patent Application No. 61/048,075, filed on Apr. 25, 2008: vidual. Tinea spreads readily, as those infected are contagious U.S. Provisional Patent Application No. 61/129,962, filed on even before they show symptoms of the disease. Participants Aug. 1, 2008; and U.S. Provisional Patent Application No. in contact sports Such as wrestling have a risk of contracting 61/115,879, filed on Nov. 18, 2008. The contents of these applications are incorporated herein by reference in their the fungal infection through skin-to-skin contact. entirety. 0006 Tinea is mildly contagious. Tinea is also a common infection in domestic animals, especially farm animals, dogs and cats and even Small pets like hamsters or guinea pigs. FIELD OF INVENTION Humans can contract tinea (also commonly referred to as 0002 The present invention relates to methods for treat “ringworm”) from these animals as humans are in close con ing, killing, and/or inhibiting the growth of fungal, yeast, and tact with them. Tinea can also be caught from other humans, mold pathogens in human Subjects comprising topically both by direct contact and by prolonged contact with flakes of administering to a human Subject in need thereofa nanoemul shed skin (from sharing clothes or from house dust, for sion composition having antifungal, anti-yeast, and/or anti instance). mold properties. The present invention also relates to meth 0007. The best known sign of tinea in people is the appear ods for treating, preventing, and/or completely curing fungal, ance of one or more red raised itchy patches with defined yeast, and/or mold infections in human Subjects comprising edges, not unlike the herald rash of Pityriasis rosea. These topically administering to a human Subject in need thereof a patches are often lighter in the center, taking on the appear nanoemulsion composition having antifungal, anti-yeast, ance of a ring with hyperpigmentation around the circumfer and/or anti-mold properties. ence caused by an increase in melanin. If the infected area involves the scalp or beard area, then bald patches may BACKGROUND OF THE INVENTION become evident. The affected area may become itchy for periods of time. A. Fungal/Yeast/Mold Infections 0008. Sometimes a tinea infection may cause skin lesions 0003) Fungi cause a wide variety of diseases in humans. in a part of the body that is remote from the actual infection. While some fungi cause infections limited to the outermost Such lesions are called “dermatophytids'. The lesions them layers of the skin and hair (Superficial mycoses), other fungi selves are fungus-free, and normally disappear upon treat cause cutaneous mycoses by penetrating to the keratinized ment of the actual infection. The most common example is an layers of the skin, hair and nails and triggering pathologic eruption in the hands resulting from a fungus infection of the changes in the host. Subcutaneous mycoses cause infections feet. Dermatophytids are essentially a generalized allergic in the dermis, Subcutaneous tissues, muscle and fascia and are reaction to the fungus. often chronic. Systemic mycoses originate primarily in the 0009. Thus, fungi and yeast such as Microsporum species, lung and may cause secondary infections in other organ sys Trichophyton species, Epidermophyton species, and Candida tems in the body. Patients with immune system deficiencies species can cause persistent and difficult to treat infections. are often prone to opportunistic mycoses. 00.10 Examples of Microsporum species include M. canis 0004 Dermatophytes, including Trichophyton rubrum and M. gypseum. Microsporum is one of the several fungal and Trichophyton mentagrophytes, are responsible for fungal genera that cause dermatophytosis. Dermatophytosis is a infections of the skin or Dermatophytoses (dermatophytose). general term used to define the infection in hair, skin or nails Tinea pedis is a skin infection that most often manifests due to any dermatophyte species. Similar to other dermato between the toes, causing scaling, flaking and itching of the phytes, Microsporum has the ability to degrade keratin and affected skin. Blisters and cracked skin may also occur, lead thus can reside on skin and its appendages and remains non ing to exposed raw tissue, erythema, pain, Swelling and invasive. Notably, Microsporum spp. mostly infect the hair inflammation. A second type of tinea pedis is called the moc and skin. Microsporum canis is the principal cause of ring casin tinea pedis and is characterized by chronic plantar worm in dogs and cats and a Zoophilic fungal species causing erythema with slight scaling to diffuse hyperkeratosis that can sporadic dermatophytosis in humans, especially tinea capitis be asymptomatic or pruritic. Other types include inflamma in children with cats and dogs. tory/vesicular and ulcerative tinea pedis.
Recommended publications
  • Proper Preop Makes for Easier Toenail Surgery

    Proper Preop Makes for Easier Toenail Surgery

    April 15, 2007 • www.familypracticenews.com Skin Disorders 25 Proper Preop Makes for Easier Toenail Surgery BY JEFF EVANS sia using a digital block or a distal approach to take ef- Senior Writer fect. Premedication with NSAIDs, codeine, or dextro- propoxyphene also may be appropriate, he said. WASHINGTON — Proper early management of in- To cut away the offending section of nail, an English grown toenails may help to decrease the risk of recur- anvil nail splitter is inserted under the nail plate and the rence whether or not surgery is necessary, Dr. C. Ralph cut is made all the way to the proximal nail fold. The hy- Daniel III said at the annual meeting of the American pertrophic, granulated tissue should be cut away as well. Academy of Dermatology. Many ingrown toenails are recurrent, so Dr. Daniel per- “An ingrown nail is primarily acting as a foreign-body forms a chemical matricectomy in nearly all patients after reaction. That rigid spicule penetrates soft surrounding tis- making sure that the surgical field is dry and bloodless. sue” and produces swelling, granulation tissue, and some- The proximal nail fold can be flared back to expose more times a secondary infection, said Dr. Daniel of the de- of the proximal matrix if necessary. Dr. Daniel inserts a Cal- partments of dermatology at the University of Mississippi, giswab coated with 88% phenol or 10% sodium hydroxide Jackson, and the University of Alabama, Birmingham. and applies the chemical for 30 seconds to the portion of For the early management of stage I ingrown toenails the nail matrix that needs to be destroyed.
  • Nail Problems

    Nail Problems

    Nail Problems Components of the Nail Congenital Disorders Racket nails, characterized by a broad short thumb nail, is the commonest congenital nail defect, dominantly inherited and seen in 1% of the population. The basic abnormality is shortness of the underlying terminal phalanx. In the yellow nail syndrome, the nail changes begin in adult life, against a background of hypoplasia of the lymphatic system. Peripheral edema is usually present and pleural effusions may occur. The nails grow very slowly and become thickened and greenish-yellow; their surface is smooth but they are over curved from side to side. Acquired Nail Changes Beau's Lines Transverse lines or grooves in nail. Causes include any severe systemic illness or medications (chemotherapy), which affects growth of the nail matrix. Clinically: The grooves or lines move distally; the distance from the nail fold lets one assess the time of trauma. Onycholysis Separation of nail from nail bed. Causes include psoriasis, dermatitis, fungal infections; medications (photo-onycholysis from tetracyclines or psoralens), thyroid disease; rarely inherited. Idiopathic onycholysis is most common among women; painless separation of nail without apparent cause. Typically, the distal third separates and underlying nail bed becomes darker and thickened. Therapy: Cut nail very short to reduce leverage encouraging separation, apply antifungal solution. Usually self-limited process. Ingrown Nail Penetration of nail plate into tissue of lateral nail fold. Almost always involves great toes. Causes include congenital malformation of nail (pincer nail), improper trimming, and tightly fitting shoes. Clinically: Distorted nail with swelling, pain, and granulation tissue along the lateral nail fold. Therapy: Mild cases: Eliminate pressure, trim nail; topical antiseptics as foot soaks or on small piece of cotton wool pushed under affected nail.
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix

    Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix

    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T

    WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
  • Proper Preop Makes for Easier Toenail Surgery

    Proper Preop Makes for Easier Toenail Surgery

    20 Dermatologic Surgery S KIN & ALLERGY N EWS • April 2007 Proper Preop Makes for Easier Toenail Surgery BY JEFF EVANS produces swelling, granulation tissue, and tor or a 1- to 2-mm curette. has served as a speaker, consultant, and in- Senior Writer sometimes a secondary infection, said Dr. He also uses a technique for early-stage vestigator for the company. Daniel of the departments of dermatol- ingrown toenails in which dental floss is in- A procedure that uses an acrylic-affixed WASHINGTON — Proper early man- ogy at the University of Mississippi, Jack- serted under the ingrown nail corner with- gutter splint has been reported to be suc- agement of ingrown toenails may help to son, and the University of Alabama, Birm- out anesthesia and is kept there to separate cessful for avoiding surgery, Dr. Daniel decrease the risk of recurrence whether or ingham. the nail edge from adjacent soft tissue (J. said. A plastic gutter tube is set under the not surgery is necessary, Dr. C. Ralph For the early management of stage I in- Am. Acad. Dermatol. 2004;50:939-40). ingrown part of the nail and acrylic is Daniel III said at the annual meeting of the grown toenails in which some granula- Dr. Daniel formerly was on the board of sculpted and allowed to polymerize American Academy of Dermatology. tion tissue but no infection is present, Dr. directors for Doak Dermatologics, a sub- around the ingrown part of the nail and “An ingrown nail is primarily acting as Daniel has trained his nurse to push wisps sidiary of Bradley Pharmaceuticals Inc., hold the gutter tube in place.
  • Ingrown Nail/Paronychia Referral Guide: Podiatry Referral Page 1 of 1 Diagnosis/Definition

    Ingrown Nail/Paronychia Referral Guide: Podiatry Referral Page 1 of 1 Diagnosis/Definition

    Ingrown Nail/Paronychia Referral Guide: Podiatry Referral Page 1 of 1 Diagnosis/Definition: Redness, warmth, tenderness and exudate coming from the areas adjacent to the nail plate. Initial Diagnosis and Management: History and physical examination. In chronic infection appropriate radiographic (foot or toe series to rule out distal phalanx osteomyelitis) and laboratory evaluation (CBC and ESR). Ongoing Management and Objectives: Primary care should consist of Epsom salt soaks, or soapy water, and antibiotics for ten days. If Epsom salt soaks and antibiotics are ineffective, the primary care provider has the following options: Reevaluate and refer to podiatry. Perform temporary avulsion/I&D. Perform permanent avulsion followed by chemical cautery (89% Phenol or 10% NaOH application – 3 applications maintained for 30 second intervals, alcohol dilution between each application). Aftercare for all of the above is continued soaks, daily tip cleaning and bandage application. Indications for Specialty Care Referral: After the reevaluation at the end of the antibiotic period the primary care provider can refer the patient to Podiatry for avulsion/ surgical care if they do not feel comfortable performing the procedure themselves. The patient should be given a prescription for antibiotics renewal and orders to continue soaks until avulsion can be performed. Test(s) to Prepare for Consult: Test(s) Consultant May Need To Do: Criteria for Return to Primary Care: After completion of the surgical procedure, patients will be returned to the primary care provider for follow-up. Revision History: Created Revised Disclaimer: Adherence to these guidelines will not ensure successful treatment in every situation. Further, these guidelines should not be considered inclusive of all accepted methods of care or exclusive of other methods of care reasonably directed to obtaining the same results.
  • Malassezia Furfur Folliculitis in Cancer Patients. the Need for Interaction Of

    Malassezia Furfur Folliculitis in Cancer Patients. the Need for Interaction Of

    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 23, No. 5 Copyright © 1993, Institute for Clinical Science, Inc. Malassezia furfur Folliculitis in Cancer Patients The Need for Interaction of Microbiologist, Surgical Pathologist, and Clinician in Facilitating Identification by the Clinical Microbiology Laboratory* RAMON L. SANDIN, M.D., M.S.,f TZANN-TARN FANG, M.D.,* JOHN W. HIEMENZ, M.D.,t JOHN N. GREENE, M.D.,§ LINA CARD, M.T. (ASCP),t ALEXANDRA KALIK, M.D.,t and JENO E. SZAKACS, M.D.t Departments of Pathology, f Bone Marrow Transplant Service,t and Infectious Diseases,§ H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612-9497 ABSTRACT Malassezia furfur (MF) is a lipophilic yeast which can be found as a member of the indigenous microbiota of human skin. In immunocompro­ mised transplant patients, MF can cause a distinctive folliculitis which is a clinical look-alike to Candida folliculitis, the latter of more potentially devastating significance. Recovery of MF in culture is dependent upon the addition to culture media of an exogenous source of fatty acids, such as olive oil. The addition of an extra Sabourauds plate with an olive oil overlay to the routine set of media used to inoculate all skin biopsy specimens in order to detect MF is labor-intensive and not cost-effective. Thus, MF may not be isolated in cases of MF folliculitis unless the clinical microbiology laboratory is put on alert by the clinical suspicions of the attending physi­ cian, or by histopathologic findings suggestive of folliculitis revealed by review of surgical pathology slides.
  • Ingrown Toenails

    Ingrown Toenails

    POST-OP NAIL CARE The day following the procedure, remove the bandage and begin soaking the toe for 10-15 minutes at least once daily. If the bandage does not come off easily, soak in warm water with one (1) tablespoon Epson Salts. As you soak, use a cotton tipped applicator (Q-tip) to clean the nail groove. Also, gently pull the skin edges back from the area where the nail was removed to be sure that any draining is released. After drying the toes, apply a light amount of triple antibiotic ointment (Neosporin) or other topical anesthetic, and light gauze or a bandage (Band-aid). Gauze is best to absorb INGROWN drainage. After a few days, the toe may be Brian Gardner, D.P.M. TOENAILS overly moist and need to dry. Use less triple antibiotic, continue soaking, Podiatrist and dress with light gauze or a Dr. Brian Gardner specializes in bandage (Band-aid). As drying foot and ankle surgery, wound care, occurs, tenderness will usually biomechanics, sports medicine, decrease. Continue soaks until the diabetic foot care, area is no longer draining (usually and general foot care. several weeks, if the nail root was treated with a chemical). facebook.com/UintahBasinHealthcare www.ubh.org 435.725.2025, Roosevelt 435.781.2030, Vernal 250 W 300 N Clinic #2 Suite 203 (Level 2), Roosevelt, Utah 379 N 500 W, Vernal, Utah Nails grow from a root beneath the skin TREATMENT IMPORTANT called the “matrix.” This growth center TREATMENT INFORMATION can vary in size and shape. It may Initially, your doctor may be able to produce a nail which is flat, curved, trim the ingrown toenail.
  • WO 2009/132342 Al

    WO 2009/132342 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132342 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/107 (2006.01) A61P 31/10 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (21) International Application Number: EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2009/04181 1 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 27 April 2009 (27.04.2009) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (25) Filing Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (26) Publication Language: English UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/048,075 25 April 2008 (25.04.2008) US kind of regional protection available): ARIPO (BW, GH, 61/129,962 1 August 2008 (01 .08.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 61/1 15,879 18 November 2008 (18.1 1.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicant (for all designated States except US): ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, NANOBIO CORPORATION [US/US]; 23 11 Green MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), Road, Suite A, Ann Arbor, MI 48105 (US).
  • Therapies for Common Cutaneous Fungal Infections

    Therapies for Common Cutaneous Fungal Infections

    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
  • WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT

    WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 7/60 (2006.01) G01N 33/53 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CI2Q 1/18 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (21) International Application Number: KM, ML, MR, NE, SN, TD, TG). PCT/US2017/063696 (22) International Filing Date: Published: 29 November 201 7 (29. 11.201 7) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/427,507 29 November 2016 (29. 11.2016) US 62/484,696 12 April 2017 (12.04.2017) US 62/53 1,767 12 July 2017 (12.07.2017) US 62/541,474 04 August 2017 (04.08.2017) US 62/566,947 02 October 2017 (02.10.2017) US 62/578,877 30 October 2017 (30.10.2017) US (71) Applicant: CIDARA THERAPEUTICS, INC [US/US]; 63 10 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US). (72) Inventors: BARTIZAL, Kenneth; 7520 Draper Avenue, Unit 5, La Jolla, CA 92037 (US). DARUWALA, Paul; 1141 Luneta Drive, Del Mar, CA 92014 (US). FORREST, Kevin; 13864 Boquita Drive, Del Mar, CA 92014 (US).
  • | Oa Tai Ei Rama Telut Literatur

    | Oa Tai Ei Rama Telut Literatur

    |OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn .